Yıl: 2014 Cilt: 51 Sayı: 1 Sayfa Aralığı: 63 - 68 Metin Dili: Türkçe İndeks Tarihi: 29-07-2022

Therapeutic plasma exchange in neurologic diseases: an experience with 91 patients in seven years ***

Öz:
Giriş: Bu çalışmada, terapötik plazma değişimi (TPD) ile tedavi ettiğimiz nöro- immünolojik olgulara ait 7 yıllık deneyimimizin sonuçları rapor edilmiştir. Yön­tem­: TPD uyguladığımız 91 olgunun (53 erkek, 38 kadın) medikal kayıtları geriye dönük olarak incelenmiştir. Bul­gu­lar: Tanısal olarak sınıflandığında, bu olguların 60ının Guillain- Barre sendromu (GBS), 23ünün Miyastenia Gravis (MG), 4ünün ise kronik inflammatuar demiyelinizan polinöropati (KİDP) tanısıyla TPD aldığı görülmüştür. Birer olguya ise, polimiyozit, septik ensefalopati, akut dissemine ensefalomiyelit (ADEM) ve Opsoklonus-Myoklonus sendromu (OMS) tanılarıyla TPD uygulanmıştır. GBS hastalarımızın %26,7sinde tam düzelme, %61,7sinde kısmi düzelme izlenmiş olup, disabilitesi yüksek %11,7 hasta solunum yetmezliği nedeniyle kaybedilmiştir. MGli hastaların %13,4ünde tedaviye rağmen ölüm, %78inde tam klinik düzelme gözlenmiştir. KIDPli 4 hastamızın üçünde total, birinde kısmi düzelme gözlenmiş, ADEMli olgumuz TPD ile önce kısmen düzelmiş ancak tedaviden 2 ay sonra aspirasyon pnömonisine bağlı solunum yetmezliği nedeniyle kaybedilmiş, polimiyozitli olgumuzda kısmi, septik ensefalopati ve OMSli hastalarımızda tam düzelme gözlenmiştir. TPE uygulamasında karşılaştığımız yan etkiler hipotansiyon, hipokalsemi ve anemi gibi hafif ve yönetilebilir düzeydedir. So­nuç: Çalışmamızın sonuçları otoimmün kökenli nörolojik hastalıklarda TPE tedavisinin etkili ve güvenilir bir yöntem olduğunu göstermektedir.
Anahtar Kelime:

Konular: Nörolojik Bilimler Psikiyatri

Nörolojik hastalıklarda terapötik plazma değişimi: 91 hasta ile yedi yıllık deneyim sonuçları

Öz:
Introduction: In this study, we report the results of our experience of therapeutic plasma exchange (TPE) for neuroimmunologic disorders performed at our hospital over a seven-year period. Met­hods: We retrospectively reviewed the medical records of 91 patients (53 male, 38 female) who had been treated at our center with TPE. Re­sults: 60 patients with Guillain-Barrè syndrome (GBS), 23 with myasthenia gravis (MG), 4 with chronic inflammatory demyelinating polyneuropathy (CIDP) and 1 patient each with polymyositis, septic encephalopathy, acute disseminated encephalomyelitis (ADEM) and Opsoclonus-Myoclonus syndrome (OMS) received TPE. 26.7% of GBS patient s made complete recovery, 61.7% had partial recovery and 11.7% patients died due to respiratory failure. Despite our best efforts and effective TPE treatments, 13.4% of MG patients deceased, however, 78% had full recovery. Three patients with CIDP were discharged with full and 1 patient with partial recovery. The patient with ADEM had partial recovery with TPE at first, but deceased 2 months later due to pneumonia-related respiratory insufficiency. While, patient with polymyositis had slight-partial recovery, we obtained full recovery with TPE in septic encephalopathy and OMS patients. The side effects and complications of treatments with TPE, which included hypotension, hypocalcaemia and anemia, were mild and manageable. Conc­lu­si­on: The improvement rates were encouraging and we concluded that significant benefit can be achieved with TPE for the treatment of neuroimmunological disorders.
Anahtar Kelime:

Konular: Nörolojik Bilimler Psikiyatri
Belge Türü: Makale Makale Türü: Araştırma Makalesi Erişim Türü: Erişime Açık
  • 1. Hughes RAC, Swan AV, Raphael JC, Annane D, van Koningsveld R, van Doorn P. Immunotherapy for Guillain-Barré syndrome: a systematic review. Brain 2007; 130:2245-2257.
  • 2. Koç AF, Kılıç NB, Yerdelen D, Bozdemir H. Guillain-Barré syndrome; Etiology, Clinical Findings and Plasma Exchange. Journal of Neurological Sciences (Turkish) 2005; 22:267-273.
  • 3. Kuwabara S. Guillain-Barré Syndrome. Curr Neurol Neurosci Rep 2007; 7:57-62.
  • 4. Hahn AF, Bolton CF, Pillay N, Chalk C, Benstead T, Bril V, Shumak K, Vandervoort MK, Feasby TE. Plasma-exchange therapy in chronic inflammatory demyelinating polyneuropathy: a double blind, sham- controlled, crossover study. Brain 1996; 119:1055-1066.
  • 5. Dyck PJ, Daube J, O’Brien P, Pineda A, Low PA, Windebank AJ, Swanson C. Plasma exchange in chronic inflammatory demyelinating polyradiculoneuropathy. N Eng J Med 1986; 314:461-465.
  • 6. Ubogu Eroboghene E, Zaidat Osama O, Suarez José I. Acute Motor- Sensory Axonal Neuropathy Associated with Active Systemic Lupus Erythematosus and Anticardiolipin Antibodies. Journal of Clinical Rheumatology 2001; 7:326-331.
  • 7. Yücesan C, Arslan O, Arat M, Yücemen N, Ayyildiz E, Ilhan O, Mutluer N. Therapeutic plasma exchange in the treatment of neuroimmunologic disorders: Review of 50 cases. Transfusion and Apheresis Science 2007; 36:103-107.
  • 8. Tindall RSA, Rollins JA. Assessment of therapeutic plasmapheresis in demyelinating neurologic disorders. Ther Plasmapher 1986; 79:991- 997.
  • 9. Cortese I, Chaudhry V, So YT, Cantor F, Cornblath DR, Rae-Grant A. Evidence-based guideline update: Plasmapheresis in neurologic disorders. Neurology 2011; 76:294-300.
  • 10. Schilling S, Linker RA, König FB, Koziolek M, Bähr M, Müller GA, Paulus W, Gärtner J, Brück W, Chan A, Gold R. Plasma exchange therapy for steroid unresponsive multiple sclerosis relapses: Clinical experience with 16 patients. Nevenarzt 2006; 77 :430-438.
  • 11. Watanabe S, Nakashima I, Misu T, Miyazawa I, Shiga Y, Fujihara K, Itoyama Y. Therapeutic efficacy of plasma exchange in NMO-IgG positive patients with neuromyelitis optica. Mult Scler 2007; 13:128-132.
  • 12. Rodriguez M, Karnes WE, Bartleson JD, Pineda AA. Plasmapheresis in acute episodes of fulminant CNS inflammatory demyelination. Neurology 1993; 43:1100-1104.
  • 13. Shariatmadar S, Noto TA. Plasma exchange in stiff-man syndrome. The Apher 2001; 5:64-67.
  • 14. Odaka M, Yuki N, Yamada M, and et al. Bickerstaff’s brainstem encephalitis: clinical features of 62 cases and a subgroup associated with Guillain-Barre syndrome. Brain 2003; 126:2279-2290.
  • 15. Ryan LJ, Bowman R, Zantek ND, Sherr G, Maxwell R, Clark HB, Mair DC. Use of therapeutic plasma exchange in the management of acute hemorrhagic leukoencephalitis: a case report and review of the literature. Transfusion 2007; 47:981-986.
  • 16. Basic-Jukic N, Kes P, Bubic-Filipi L, Brunetta B. Treatment of thrombotic microangiopathies with plasma exchange. Hematology 2007; 12:63-67.
  • 17. Bayry J, Kazatchkine MD, Kaveri SV. Shortage of human intravenous immunoglobulin: Reasons and possible solutions. Nat Clin Ract Neurol 2007; 3:120-121.
  • 18. Hughes RAC, Newsom-Davis JM, Perkin GD, Pierce JM. Controlled trial of prednisolone in acute polyneuropathy. Lancet 1978; 2:750-753.
  • 19. Osserman KE, Genkins G. Studies in myasthenia gravis: Review of twenty year experience in over 1200 patients. Mount Sinai J Med 1971; 38:497-537.
  • 20. Hughes RA, Rees JH. Clinical and epidemiologic features of Guillain- Barre syndrome. J. Infect Dis 1997; 176:92-98.
  • 21. Van Koningsveld R, Van Doorn PA, Schmitz PI, Ang CW, Van der Meché FG. Mild forms of Guillain-Barré syndrome in an epidemiologic survey in The Netherlands.Neurology 2000; 8;54:620-625.
  • 22. Brettle RP, Gross M, Legg NJ, Lockwood M, Pallis C. Treatment of acute polyneuropathy by plasma exchange. Lancet. 1978; 18:1100.
  • 23. The Guillain-Barré syndrome Study Group. Plasmapheresis and acute Guillain-Barré syndrome. Neurology 1985; 35:1096-1104.
  • 24. Plasma Exchange / Sandoglobulin Guillain Barre Syndrome Trial Group. Randomized Trial of Plasma Exchange, Intravenous Immunoglobulin, and Combined Treatments in Guillain-Barre syndrome. Lancet 1997; 349:225-230.
  • 25. Raphael JC, Chevret S, Hughes RAC, Annane D. Plasma exchange for Guillain Barre’ syndrome. Cochrane Database Syst Rev 2002: CD001798.
  • 26. Van Doorn PA, Ruts L, Jacobs BC. Clinical features, pathogenesis, and treatment of Guillain-Barre syndrome. Lancet Neurol 2008; 7:939- 950.
  • 27. Mori M, Kuwabara S, Fukutake T, Hattori T. Intravenous immunoglobulin therapy for Miller-Fischer syndrome. Neurology 2007; 68:1144-1146.
  • 28. Gajdos P, Chevret S, Toyka K. Plasma exchange for myasthenia gravis. Cochrane Database Sys Rev 2002; 68:CD002275.
  • 29. Tzartos SJ, Barkas T, Cung MT, Mamalaki A, Marraud M, Orlewski P, Papanastasiou D, Sakarellos C, Sakarellos-Daitsiotis M, Tsantili P, Tsikaris V. Anatomy of the antigenic structure of a large membrane autoantigen, the muscle-type nicotinic acetylcholine receptor. Immunol Rev 1998; 163:89-120.
  • 30. Philips LH. The epidemiology of myasthenia gravis. Semin Neurol 2004; 24:17-20.
  • 31. Elechi CA, Shah A, Lisah RP. Infections occurring in hospitalized myasthenia gravis patients. Ann NY Acad Sci 1993; 681:561-62.
  • 32. Keesey JC. Clinical evaluation and management of myasthenia gravis. Muscle Nerve 2004; 29:484-505.
  • 33. Keesey JC. “Crisis” in myasthenia gravis: an historical perspective. Muscle Nerve 2002; 26:1-3.
  • 34. Natarajan N, Weinstein R. Therapeutic apheresis in neurology critical care. J Intensive Care Med 2005; 20:212-225.
  • 35. Weinstein R. Therapeutic apheresis in neurological disorders. J Clin Apher 2000; 15:74-128.
  • 36. Gajdos P, Chevret S, Toyka K. Intravenous immunoglobulin for myasthenia gravis. Cochrane Database Syst Rev 2006; 19:CD002277.
  • 37. Yeh JH; Chen WH, Chiu HC. Double filtration plasmapheresis in the treatment of myasthenic crisis-analysis of prognostic factors and efficacy. Acta Neurol Scand 2001; 104:78-82.
  • 38. Yeh JC, Chiu HC. Comparison between double-filtration plasmapheresis and immunoadsorption plasmapheresis in the treatment of patients with myasthenia gravis. J Neurol 2000; 247:51-53.
  • 39. Yeh S-H, Chiu HC. Plasmapheresis in myasthenia gravis. Acta Neurol Scand 1999; 99:147-151.
  • 40. Flachenecker P, Taleghani BM, Gold R, Grossmann R, Wiebecke D, Toyka KV. Treatment of severe myasthenia gravis with protein A immunoadsorbtion and cyclophosphamide. Transfus Sci 1998; 19(Suppl):43-46.
APA Karaca S, KOZANOĞLU İ, GÖKSEL KARAKURUM B, KARATAŞ M, TAN M, YERDELEN V, GİRAY S, arlier z (2014). Therapeutic plasma exchange in neurologic diseases: an experience with 91 patients in seven years ***. , 63 - 68.
Chicago Karaca Sibel,KOZANOĞLU İlknur,GÖKSEL KARAKURUM Başak,KARATAŞ MEHMET,TAN Meliha,YERDELEN V. Deniz,GİRAY Semih,arlier zulfikar Therapeutic plasma exchange in neurologic diseases: an experience with 91 patients in seven years ***. (2014): 63 - 68.
MLA Karaca Sibel,KOZANOĞLU İlknur,GÖKSEL KARAKURUM Başak,KARATAŞ MEHMET,TAN Meliha,YERDELEN V. Deniz,GİRAY Semih,arlier zulfikar Therapeutic plasma exchange in neurologic diseases: an experience with 91 patients in seven years ***. , 2014, ss.63 - 68.
AMA Karaca S,KOZANOĞLU İ,GÖKSEL KARAKURUM B,KARATAŞ M,TAN M,YERDELEN V,GİRAY S,arlier z Therapeutic plasma exchange in neurologic diseases: an experience with 91 patients in seven years ***. . 2014; 63 - 68.
Vancouver Karaca S,KOZANOĞLU İ,GÖKSEL KARAKURUM B,KARATAŞ M,TAN M,YERDELEN V,GİRAY S,arlier z Therapeutic plasma exchange in neurologic diseases: an experience with 91 patients in seven years ***. . 2014; 63 - 68.
IEEE Karaca S,KOZANOĞLU İ,GÖKSEL KARAKURUM B,KARATAŞ M,TAN M,YERDELEN V,GİRAY S,arlier z "Therapeutic plasma exchange in neurologic diseases: an experience with 91 patients in seven years ***." , ss.63 - 68, 2014.
ISNAD Karaca, Sibel vd. "Therapeutic plasma exchange in neurologic diseases: an experience with 91 patients in seven years ***". (2014), 63-68.
APA Karaca S, KOZANOĞLU İ, GÖKSEL KARAKURUM B, KARATAŞ M, TAN M, YERDELEN V, GİRAY S, arlier z (2014). Therapeutic plasma exchange in neurologic diseases: an experience with 91 patients in seven years ***. Nöropsikiyatri Arşivi, 51(1), 63 - 68.
Chicago Karaca Sibel,KOZANOĞLU İlknur,GÖKSEL KARAKURUM Başak,KARATAŞ MEHMET,TAN Meliha,YERDELEN V. Deniz,GİRAY Semih,arlier zulfikar Therapeutic plasma exchange in neurologic diseases: an experience with 91 patients in seven years ***. Nöropsikiyatri Arşivi 51, no.1 (2014): 63 - 68.
MLA Karaca Sibel,KOZANOĞLU İlknur,GÖKSEL KARAKURUM Başak,KARATAŞ MEHMET,TAN Meliha,YERDELEN V. Deniz,GİRAY Semih,arlier zulfikar Therapeutic plasma exchange in neurologic diseases: an experience with 91 patients in seven years ***. Nöropsikiyatri Arşivi, vol.51, no.1, 2014, ss.63 - 68.
AMA Karaca S,KOZANOĞLU İ,GÖKSEL KARAKURUM B,KARATAŞ M,TAN M,YERDELEN V,GİRAY S,arlier z Therapeutic plasma exchange in neurologic diseases: an experience with 91 patients in seven years ***. Nöropsikiyatri Arşivi. 2014; 51(1): 63 - 68.
Vancouver Karaca S,KOZANOĞLU İ,GÖKSEL KARAKURUM B,KARATAŞ M,TAN M,YERDELEN V,GİRAY S,arlier z Therapeutic plasma exchange in neurologic diseases: an experience with 91 patients in seven years ***. Nöropsikiyatri Arşivi. 2014; 51(1): 63 - 68.
IEEE Karaca S,KOZANOĞLU İ,GÖKSEL KARAKURUM B,KARATAŞ M,TAN M,YERDELEN V,GİRAY S,arlier z "Therapeutic plasma exchange in neurologic diseases: an experience with 91 patients in seven years ***." Nöropsikiyatri Arşivi, 51, ss.63 - 68, 2014.
ISNAD Karaca, Sibel vd. "Therapeutic plasma exchange in neurologic diseases: an experience with 91 patients in seven years ***". Nöropsikiyatri Arşivi 51/1 (2014), 63-68.